

DAY	POSTER HALL	TIME/TYPE	311	312	302-304	BALLROOM A	BALLROOM B-C	AUDITORIUM	TIME/TYPE	DAY	
SUNDAY 2/27/11	Poster Set-up 8 am-8:30 pm	9 am-2:30 pm Workshop					1. PC Workshop for New Investigators and Trainees			9 am-2:30 pm Workshop	SUNDAY 2/27/11
		2:30-4:30 pm Workshop			2. Frontiers in Lab Sci	3. Trials Design			2:30-4:30 pm Workshop		
	5-7 pm Opening							4. 16 th Bernard Fields Lecture 5 th N'Galy-Mann Lecture	5-7 pm Opening		
		7-8:30 pm Welcome Reception							7-8:30 pm Welcome Reception		
MONDAY 2/28/11	Posters Open 7 am-7 pm	8:30-9 am Plenary							5. Science and Practice of HIV Prevention in the US	8:30-9 am Plenary	MONDAY 2/28/11
		9-9:30 am Plenary							6. Neutralizing Antibody Response to HIV	9-9:30 am Plenary	
		10 am-12 n Oral Abstracts			7. HIV-Host Interaction	10 am-12:15 pm 8. HIV Prevention: HSV-2, Topical and Oral PrEP, and Circumcision	9. TB and Opportunistic Diseases	10. Research on Delivery of Care in Developing Countries	11. HIV: Innovative Therapeutic Approaches, ART, and Drug Resistance	10 am-12 n Oral Abstracts	
		1-2 pm Themed Discussion	12. Molecular Epidemiology: Primate Viruses and How They Affect Humans	13. Genomics and Pharmacogenetics: HIV Disease Progression, ARV Toxicity, and Response to HCV Therapy	14. ART Use and Outcomes among Youth	15. Cervical Cancer Screening in the Developing World: Lessons from Africa	16. Retention and Adherence to Care in Resource-limited Settings			1-2 pm Themed Discussion	
		2-4 pm Poster Abstracts								2-4 pm Poster Abstracts	
	4-6 pm Symposia + Oral Abstracts			Oral Abstracts Session 17. Viral and Host Factors in HIV-associated Neurological Disease	18. Anti-HIV Antibodies	19. Responding to Risk	20. HAART at 15	4-6 pm Symposia + Oral Abstracts			
TUESDAY 3/1/11	Posters Open 7 am-7 pm	8:30-9 am Plenary							21. Cost-effectiveness in HIV Care: Understanding Value in a World of Limited Resources	8:30-9 am Plenary	TUESDAY 3/1/11
		8:30-9 am Plenary							22. The Structure of Retroviral Integrase and the Mechanism of Strand Transfer Inhibitor Action	8:30-9 am Plenary	
		10 am-12 n Oral Abstracts			23. HIV Complications	24. Virus-Cell Interaction and Co-factors	25. Advances in PrEP			10 am-12 n Oral Abstracts	
		1-2 pm Themed Discussion	26. Hematologic Malignancies	27. Pharmacologic Considerations for Therapeutic Success or Failure in Resource-limited Settings	28. Microbial Translocation and Immune Activation in HIV Infection and Therapy	29. HAART during Pregnancy and Pre-term Delivery	30. Cryptococcal Meningitis and Other Cryptic Diseases			1-2 pm Themed Discussion	
		2-4 pm Poster Abstracts								2-4 pm Poster Abstracts	
	4-6 pm Symposia + Oral Abstracts			31. HPV Challenges and Opportunities	32. Innate Immunity and Restriction Factors	33. Getting the Most from Global HIV Scale-up	Oral Abstracts Session 34. HCV Pathogenesis, Treatment, and Resistance	4-6 pm Symposia + Oral Abstracts			
WEDNESDAY 3/2/11	Posters Open 7 am-7 pm	8:30-9 am Plenary							35. Drugs for Prevention-Topical and Systemic PrEP	8:30-9 am Plenary	WEDNESDAY 3/2/11
		9-9:30 am Plenary							36. New Antiviral Therapies in the Management of HCV Infection	9-9:30 am Plenary	
		10 am-12 n Oral Abstracts			37. MTCT and HIV in Children	38. HIV Transmission: Old Problems and New Insights	39. HIV Immunopathogenesis and Protection	40. New HIV and HCV Antiviral Agents, Prevention, and ARV Strategies	10 am-12 n Oral Abstracts		
	1-2 pm Themed Discussion	41. Biomarkers Linked to Cognitive Dysfunction	42. Community Viral Load	43. XMRV: New Findings and Controversies	44. Is HIV Drug Resistance Spreading?	45. Atherosclerosis and HIV: Risk Factors and Pathogenesis			1-2 pm Themed Discussion		
	2-4 pm Poster Abstracts								2-4 pm Poster Abstracts		
	4-6 pm Symposia + Oral Abstracts			Oral Abstracts Session 46. Factors Important in HIV Transmission	47. Obstacles to a Cure	48. Colliding Epidemics: Controlling HIV-related TB	49. The HIV Epidemic at 30	4-6 pm Symposia + Oral Abstracts			